Event Details

Aptose Biosciences Inc. at AACR Annual Meeting 2018, Chicago, IL.

Sunday, April 15, 2018 at 1:00 PM EDT to Tuesday, April 17, 2018 at 11:59 PM EDT

Description

Date & Time: Sunday, April 15, 2018, 1:00 p.m. - 5:00 p.m. CDT

 

CG’806, a first-in-class pan-FLT3/pan-BTK inhibitor, demonstrates superiority to other FLT3 and BTK inhibitors against primary patient samples 
View Poster
Session Category: Experimental and Molecular Therapeutics
Session Title: Experimental Agents and Combinations for Hematologic Malignancies 1
Abstract Number: 4316
Location: McCormick Place South, Exhibit Hall A, Poster Section 37

 

CG’806, a first-in-class pan-FLT3/pan-BTK inhibitor, targets multiple pathways to kill diverse subtypes of acute myeloid leukemia and B-cell malignancy in vitro
View Poster
Session Title: Experimental Agents and Combinations for Hematologic Malignancies 1
Abstract Number: 4239
Location: McCormick Place South, Exhibit Hall A, Poster Section 37

 

Date & Time: Tuesday, April 17, 2018, 1:00 p.m. - 5:00 p.m. CDT

 

2018 AACR Poster APTO-253 is a new addition to the repertoire of drugs that can exploit DNA BRCA1/2 deficiency
View Poster
Session Title: DNA Damage and Cell Cycle Regulation Experimental Therapeutics
Abstract Number: 2138
Location: McCormick Place South, Exhibit Hall A, Poster Section 38